ArticleBlood2019

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.

Jennifer R Brown et al.PubMed ↗Publisher ↗

No numbers read from the abstract.